Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 10

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 10
---
ments—Warrant Exercises” below for additional information). We
expect that we will be able to demonstrate compliance with the Nasdaq stockholders’ equity requirement as a result of this offering
and the aforementioned financings and warrant exercises.

First November 2025 Registered Direct Offering

On November 13, 2025, we entered
into a definitive securities purchase agreement with investors for the purchase and sale of (i) 958,222 common shares, and (ii) pre-funded
warrants to purchase up to 2,984,146 common shares, in a registered direct offering, or the First November 2025 Offering, at a purchase
price of $0.20 per common share and $0.1999 per pre-funded warrant.

The pre-funded warrants are
immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire
until exercised in full.

The First November 2025 Offering
closed on November 13, 2025. The aggregate gross proceeds to the Company were approximately $0.788 million.

<div align='center'>S-3</div>

Second November 2025 Registered Direct Offering

On November 17, 2025, we entered
into a definitive securities purchase agreement with investors for the purchase and sale of (i) 3,991,768 common shares, and (ii) pre-funded
warrants to purchase up to 1,518,000 common shares, in a registered direct offering, or the Second November 2025 Offering, at a purchase
price of $0.25 per common share and $0.2499 per pre-funded warrant.

The pre-funded warrants are
immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire
until exercised in full.

The Second November 2025 Offering
closed on November 17, 2025. The aggregate gross proceeds to the Company were approximately $1.377 million.

Warrant Exercises

As of the date hereof, investors
from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894,769 common shares, including warrants
to purchase 1,881,250 common shares on a cashless basis. As a result, we issued an aggregate of 2,090,987 common shares and received aggregate
gross proceeds of approximately $183,